中国慢加急性肝衰竭框架在慢加急性肝衰竭中的表现:一项覆盖所有病因的多队列研究
该研究基于5288例慢性肝病急性恶化患者,评估欧洲CLIF与中国COSSH标准对慢加急性肝衰竭的诊断与预后效能,并在三个非亚洲队列中验证。中国慢加急性肝衰竭框架(原COSSH-ACLFs)较CLIF标准识别更多患者,其预后评分在肝移植-free死亡率上预测价值最高,并在非亚洲队列中表现可比。
要点
- 中国标准较CLIF标准多识别22.6%的慢加急性肝衰竭患者,含14.2%非HBV患者。
- 中国标准严重度分级分布更合理,1-3级占比63.4%/27.5%/9.1%,CLIF为25.8%/56.3%/17.9%。
- COSSH-ACLF II评分对28天/90天肝移植-free死亡率预测价值最高,优于CLIF-C ACLF等评分。
核心结论
- 本研究评估了中国慢加急性肝衰竭框架在不同病因和严重度慢加急性肝衰竭中的广泛适用性,结果可能为统一慢加急性肝衰竭诊断与预后系统提供有价值的基础。
研究设计与样本
- 研究纳入5288例(从7388例筛查中排除后)各种病因慢性肝病急性恶化患者,评估欧洲CLIF和中国COSSH标准的效能,并用三个非亚洲队列验证结果。
主要发现
- CLIF标准将844例归为慢加急性肝衰竭(28天/90天肝移植-free死亡率40.7%/57.0%;非HBV病因321例,HBV病因523例),COSSH标准将2038例归为慢加急性肝衰竭(死亡率27.3%/41.0%;非HBV病因602例,HBV病因1436例)。
- COSSH标准较CLIF标准多识别22.6%(1194/5288)患者(死亡率19.1%/31.4%),包括14.2%非HBV患者(死亡率15.9%/33.3%)。
- COSSH标准严重度分级分布更呈金字塔样(1-3级:63.4%/27.5%/9.1%),CLIF标准为25.8%/56.3%/17.9%。
- COSSH-ACLF II评分对肝硬化和所有病因慢加急性肝衰竭患者的28天/90天肝移植-free死亡率预测价值最高,优于CLIF-C ACLF和其他评分。
- 中国慢加急性肝衰竭框架(由COSSH-ACLFs更名)在三个非亚洲队列中验证表现可比。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute-on-chronic liver failure (ACLF) of various aetiologies is a complex syndrome with high short-term mortality and significant global burden. OBJECTIVE: To explore easily applicable diagnostic criteria and an accurate prognostic score for ACLF. DESIGN: Clinical data from 5288 patients (after exclusions from 7388 screened) with acute deterioration of chronic liver disease across various aetiologies were used to evaluate the performance of European Chronic Liver Failure (CLIF) and Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria. Three non-Asian cohorts were performed to validate the results. RESULTS: CLIF criteria categorised 844 patients as ACLF (28-day/90-day liver transplantation (LT)-free mortality: 40.7%/57.0%; 321 with non-hepatitis B virus (HBV) aetiology, 523 with HBV aetiology), while COSSH criteria categorised 2038 patients as ACLF (mortality: 27.3%/41.0%; 602 with non-HBV aetiology, 1436 with HBV aetiology). COSSH criteria identified 22.6% (1194/5288) more patients (mortality: 19.1%/31.4%) compared with CLIF criteria, including 14.2% non-HBV patients (mortality: 15.9%/33.3%). COSSH criteria produced a more reasonable epidemiological pyramid-like distribution across severity grades (grades 1-3: 63.4%/27.5%/9.1% vs CLIF's grades 1-3: 25.8%/56.3%/17.9%). COSSH-ACLF II score showed the highest predictive values for 28-day/90-day LT-free mortality in both cirrhotic and all ACLF patients with various aetiologies, outperforming the CLIF-C ACLF and other scores. The comparable performance of China-CLIFs (renamed from COSSH-ACLFs) was validated in three non-Asian cohorts. CONCLUSIONS: This study evaluated the broader applicability of the China-CLIF framework across diverse aetiologies and varying severity levels of ACLF. These findings may provide a valuable foundation for harmonising ACLF diagnostic and prognostic system.
引用
- Luo J, Hu M, Feng T, et al. Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies. Gut. 2025. PMID: 40713188. doi:10.1136/gutjnl-2025-335651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。